Week In Review: Fosun Signs $840 Million Deal For US Rights To Henlius' PD-1
November 19, 2022 at 14:00 PM EST
Fosun Pharma announced it has licensed US rights to a PD-1 candidate from Henlius Biotech in an $840 million agreement. Meanwhile, Tenacia Biotechnology in-licensed greater China rights to a seizure therapy from Philadelphia’s Marinus Pharma.
